MRTX-1719

Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.

Bayer has entered into a global licensing agreement with Chinese biotech Puhe BioPharma for an oral PRMT5 inhibitor (BAY 3713372) that selectively targets MTAP-deleted tumors, which occur in 10-30% of all cancers.

IDEAYA Biosciences advances multiple oncology programs, with over 230 patients enrolled in potential registration-enabling trial for darovasertib in metastatic uveal melanoma, targeting key readouts by end of 2025.

Ideaya Biosciences reports positive Phase 1 data for IDE397, a MAT2A inhibitor, in urothelial and non-small cell lung cancer patients with MTAP-deletion.